Pharmacology Research Institute   Report issue

For profit Phase 2 Phase 3 Phase 4
Founded: Irvine CA United States (1975)
Status: No NME R&D (1975)

Organization Overview

First Clinical Trial
2005
NCT00239954
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2009

Timeline

NOW
  • Now

Active Ingredients

Drugs in Phase 4 Trials (1)

tacrolimus (prograf) (1 trial)

Drugs in Phase 3 Trials (1)

escitalopram (lexapro) (1 trial)

Drugs in Phase 2 Trials (5)

bapineuzumab (1 trial)

bupropion (wellbutrin) (1 trial)

naltrexone (revia) (1 trial)

pagoclone (1 trial)

vilazodone (viibryd) (1 trial)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Alzheimer Disease (Phase 2)

Depression (Phase 3)

Depressive Disorder (Phase 3)

Depressive Disorder, Major (Phase 3)

Overweight (Phase 2)

Stuttering (Phase 2)

Tobacco Use Disorder (Phase 2)

Overview

  • Highest Phase: Phase 4
  • # of Trials: 6
  • # of Trial APIs: 7